Non-interventional, post-authorization safety study (PASS) of patients treated with commercially available liso-cel (lisocabtagene maraleucel) for large B-cell lymphomas (JCAR017-BCM-005)

20/03/2023
20/07/2026
EU PAS number:
EUPAS103855
Study
Ongoing
Subscribe
Download as PDF
Documents
Study protocol
Initial protocol

jcar017-bcm-005-pass-prot 30-aug-2022-redacted-v2

English (736.05 KB - PDF) View document
Updated protocol

jcar017-bcm-005-pass-protamend03_redacted 16Jun26.pdf

First published: 17/07/2026
English (9.65 MB - PDF) View document
Study results
Study report
Other information